Clinical Trial

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-13
notable Trial sites reduced: 241 -> 234 locations 2026-08-13
Trial Details
NCT Number NCT02960022
Lead Sponsor Astellas Pharma Global Development, Inc.
Collaborators: Pfizer
Conditions Prostate Cancer
Enrollment 900 participants
Start Date 2016-12-22
Primary Completion 2029-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12